GENE ONLINE|News &
Opinion
Blog

2022-04-14| China

Backed by RTW, LENZ Therapeutics Inks $110 Vision Loss Pact with China’s JIXING

by Joy Lin
Share To

LENZ Therapeutics, a San Diego-based clinical biopharma has announced a licensing deal worth $100 million with Shanghai-based Ji Xing Pharmaceuticals (JIXING) to develop two candidates for presbyopia. Additionally JIXING backer RTW Investments will invest $10 million in LENZ.    

Under the agreement, JIXING will pay $15 million upfront and up to $95 million in milestones in exchange for development and marketing rights to LENZ’s presbyopia treatments LNZ100 (aceclidine) and LNZ101 (aceclidine + beimonidine). LENZ will also get royalty payments based on future product sales. 

 

Eye Drops for Presbyopia  

 

Presbyopia is the gradual loss of the eye’s ability to focus on nearby objects. A natural part of the aging process, most notice it in their early to mid-forties. 

LENZ is developing eye drops to treat presbyopia. Their two candidates LNZ100 and LNZ101 contain aceclidine, a small molecule acetylcholine receptor agonist that makes the pupil contract. This creates a pinhole effect that improves near vision, without leading to a myopic shift and an increase in the degree of nearsightedness. 

Results from clinical trials on the eye drops suggest aceclidine can maintain pupil contraction for at least seven hours, and could correct distance vision. Aceclidine was well-tolerated; the most common side effect is mild discomfort when the eye drop is applied. 

LENZ is conducting INSIGHT, a clinical trial that will pave the way for a Phase 3 scheduled in the later half of 2022. 

“Age-related ophthalmic diseases are a growing challenge in China, with an estimated 440 million patients suffering from presbyopia,” said Joseph Romanelli, CEO of JIXING. “We have built a portfolio in presbyopia and dry eye disease and will continue to expand into more critical ophthalmic disease areas.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Roche Offers Up to $1 Billion for Avista to Develop Eye Disease Vectors
2022-07-20
Adverum Advances Wet AMD Gene Therapy After Cutting Jobs
2022-07-18
IPO
Belite Bio Clears Biopharma IPO Drought, with HilleVax and Tenon Medical Close Behind
2022-05-03
LATEST
Previewing AACR 2024 With Select Pre-Meeting Highlights
2024-03-28
Roche Delivering on Malaria Screening Solutions for Blood Donation
2024-03-28
Innovating Cancer Treatment: The Role of ADC Technology at Nona Biosciences
2024-03-28
BIO CHINA 2024 Brings Biotech Experts and Industry Elites Together for Innovation
2024-03-27
Galderma’s Strong European IPO Debut
2024-03-26
Markets and Mergers: Boston Scientific and Axonics Shake Hands on Deal
2024-03-25
Discover the Next Billion-Dollar Unicorn at the Biotech Innovation Funding Networking Event
2024-03-21
EVENT
2024-04-06
Biotech Innovation Funding Networking
Los Angeles, USA
Scroll to Top